210例具有11q23染色体异常的急性髓系白血病的临床分析  

The clinical analysis of 210 AML cases with 11q23 chromosome abnormalities

作　　者：刘林[1] 刘凌波[1] 邹萍[1] 王小蓓[1] 肖娟[1] 

机构地区：[1]华中科技大学同济医学院血液病研究所华中科技大学附属协和医院血液科,武汉430022

出　　处：《临床血液学杂志》2005年第3期175-177,共3页Journal of Clinical Hematology

摘　　要：目的:研究伴11q23染色体异常的成人急性髓系白血病(AML)的形态学、免疫学和临床特征。方法:对210例初治AML患者进行回顾性分析,包括细胞形态学、免疫表型、核型分析和临床资料。结果:13例AML患者存在11q23易位和缺失(发生率为6.19%),其中6例为M5a,4例为M5b,M4Eo、M3和M2各占1例。免疫表型检测显示伴11q23异常的患者除了高表达造血干/祖细胞标志分子CD34和CD117等外,通常高表达单核系统相关抗原,如CD14、CD15和CD11b。伴11q23异常组的化疗完全缓解率与正常核型对照组无明显差异(P>0.05),但无病生存期低于正常核型对照组(P<0.01)。结论:伴11q23异常的AML占所有AML的6.19%,似与单核细胞的分化阻滞相关,临床预后不良。Objective:To investigate the interrelations among morphology, immunology and clinical features in adult acute myeloid leukemia cases with 11q23 chromosome abnormalities.Method:210 de novo AML patients were retrospectively analysed on cell morphology, immunophenotyping, G-banding karyotype and clinical features.Result:13 cases were found with 11q23 rearrangements or deletion( the incidence rate was 6.19%). Immunophenotyping tests showed AML cases with 11q23 abnormalities usually expressed monocytic lineage antigens,such as CD14、CD15、CD11b,besides the marker of hemapoietic stem cell/progenitor, CD34 and CD117. The complete remission rate for the cases with 11q23 abnormalities was similar to that of the cases with normal karyotype(P> 0.05), while the median disease free survival in the former was significantly shorter than that in the latter(P< 0.01).Conclusion:The category AML with 11q23 abnormalities accounts for 6.19% of all the de novo AML cases, seems to be closely associated with monocytic differentiation, and has a poor prognosis.

关 键 词：白血病 急性 免疫表型 预后 

分 类 号：R733.7[医药卫生—肿瘤]